Lombard Strengthens Sales and Marketing
April 29 2010 - 2:01AM
RNS Non-Regulatory
TIDMLMT
Lombard Medical Technologies PLC
29 April 2010
?
Press information
Lombard Medical Technologies PLC
("Lombard Medical" or "Company")
Senior Medical Device Sales and Marketing Executive Joins Lombard Medical
London, UK, 29 April 2010 - Lombard Medical Technologies PLC (AIM: LMT),
announced today that Simon Hubbert has accepted the position of Vice President
Sales and Marketing, International and will join the Company full time on June
1st, 2010. In this role, he will lead Lombard Medical's sales and marketing
activities outside of North America.
Mr. Hubbert brings a wealth of experience to the Lombard Medical team, having
held various sales and marketing roles for Johnson & Johnson and Medtronic,
including the role of European Business and Marketing Manager for Medtronic.
Most recently, Mr. Hubbert held the position of Vice President of Sales and
Marketing International for LMA, a publicly traded company focused on innovative
medical devices for the anaesthesia markets. In his role with LMA, Mr. Hubbert
was responsible for growing revenue through a hybrid distribution model which
included a direct sales organization in several major markets, and support of
third party distribution partners in other markets. Mr. Hubbert started his
career in patient care, working in an operating theatre at a renowned
neurosurgical unit in the UK.
John Rush, Chief Executive Officer of Lombard Medical commented: "Simon's
experience is exactly what we are looking for at Lombard Medical. He has an
excellent track record of growing revenues for well known, high quality
organizations including J&J and Medtronic. He has successfully managed a
distribution model similar to one we are planning to build, and he has worked in
highly technical and clinical environments. This experience will provide an
additional level of depth to our senior team as we accelerate the launch and
roll out of Aorfix(TM) in Europe."
- Ends -
About Lombard Medical
Lombard Medical Technologies PLC (AIM: LMT), is a medical device company focused
on device solutions for the $1 billion dollar abdominal aortic aneurysm (AAA)
repair market. AAA's are a balloon-like enlargement of the aorta which, if left
untreated, may rupture and cause death. Approximately 4.5 million people are
living with AAA's in the developed world and each year 600,000 new cases are
diagnosed. The market for endovascular stent grafts for this application is
expected to grow to $1.6 billion by 2015. The Company's lead product,
Aorfix(TM), is an endovascular stent graft which has been specifically designed
to solve the problems that exist in treating complex tortuous anatomy which is
often present in advanced AAA disease. Aorfix(TM) is currently being
commercialised in the EU, with a pivotal clinical trial ongoing in the USA.
The Company is headquartered in Oxfordshire, with operations in Ayrshire and
Phoenix, USA.
Further background on the Company can be found at www.lombardmedical.com.
For further information:
+---------------------------------------+----------------------+
| | |
| Lombard Medical Technologies PLC | |
+---------------------------------------+----------------------+
| John Rush, Chief Executive Officer | Tel: 01235 750 800 |
| Tim Hall, Finance Director | |
+---------------------------------------+----------------------+
| | |
| Evolution Securities Limited | |
+---------------------------------------+----------------------+
| Barry Saint | Tel : 020 7071 4300 |
+---------------------------------------+----------------------+
| | |
| Financial Dynamics | |
+---------------------------------------+----------------------+
| Jonathan Birt /Susan Quigley | Tel : 020 7831 3113 |
+---------------------------------------+----------------------+
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEAFLPAFNEEAF
Lombard Medical Technologies (LSE:LMT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lombard Medical Technologies (LSE:LMT)
Historical Stock Chart
From Jul 2023 to Jul 2024